Literature DB >> 417409

Systemic toxic reactions to procaine penicillin G.

T F Downham, R A Cawley, S O Salley, G Dal Santo.   

Abstract

Systemic toxic were encountered in eight of 10,469 patients during or immediately following the intramuscular injection of 4,800,000 units of procaine penicillin G for the treatment of gonorrhea. Fear of imminent death, visual and auditory disturbances, violent combativeness, confusion, disorientation, and restlessness, disturbance in taste, cardiovascular changes, and grand mal seizures are the principal manifestations; these usually subside in two to 10 minutes spontaneously or after treatment. Symptoms and signs closely parallel systemic toxic reactions to local anesthetics. Pharmacokinetic analysis in dogs using 14C-procaine and 14C-procaine penicillin G showed rapid distribution of labeled drugs from plasma to cerebrospinal fluid for the intravenous as compared to the intramuscular route of administration. The animal studies were consistent with the hypothesis that the inadvertent intravenous administration of procaine penicillin G is responsible for the systemic toxic reactions. Plasma procainesterase (pseudocholinesterase) activity was assayed with an ultraviolet spectroscopic method. Substrates were procaine and procaine penicillin G. The plasma procainesterase activity of patients who had experienced systemic toxic reactions was significantly decreased as compared to that of controls, an observation not previously reported.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 417409     DOI: 10.1097/00007435-197801000-00002

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  5 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

2.  Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.

Authors:  David P McDonnell; Holland C Detke; Richard F Bergstrom; Prajakti Kothare; Jason Johnson; Mary Stickelmeyer; Manuel V Sanchez-Felix; Sebastian Sorsaburu; Malcolm I Mitchell
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

3.  Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.

Authors:  Holland C Detke; David P McDonnell; Elizabeth Brunner; Fangyi Zhao; Sebastian Sorsaburu; Victoria J Stefaniak; Sara A Corya
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

4.  Olanzapine long-acting injection: insights from an early case series in the UK.

Authors:  Deirdre McGlennon; Chris J Bushe
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

5.  Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.

Authors:  Chris J Bushe; Deborah Falk; Ernie Anand; Marta Casillas; Elena Perrin; Rashna Chhabra-Khanna; Holland C Detke
Journal:  BMC Psychiatry       Date:  2015-04-02       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.